New insights into the pathogenesis and treatment of rheumatoid arthritis

Clinical Immunology and Immunopathology

Volumn 83, Issue 2, 1997, Pages 103-116

  Odeh, Majed ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 1; INTERLEUKIN 4; METALLOPROTEINASE; TUMOR NECROSIS FACTOR;

AUTOIMMUNITY; DRUG THERAPY; ETIOLOGY; HUMAN; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS;

EID: 0030957448     PISSN: 00901229     EISSN: None     Source Type: Journal    
DOI: 10.1006/clin.1996.4296     Document Type: Review

References (209)

1. Harris E. D. Jr. Rheumatoid arthritis: Pathophysiology and implications for therapy. N. Engl. J. Med. 322:1990;1277-1289.
2. Scott D. L., Willoughby D. A., Blake D. R. Molecular insights into rheumatoid arthritis. Mol. Aspects Med. 12:1991;341-394.
3. Myllykangas-Luosujarvi R. A., Aho K., Isomaki H. A. Mortality in rheumatoid arthritis. Semin. Arthritis Rheum. 25:1995;193-202.
4. Pincus T. The paradox of effective therapies but poor long term outcome in rheumatoid arthritis.Semin. Arthritis Rheum. 21:1992;2-15.
5. Iannuzzi L., Dawson N., Zein N. Does drug therapy slow radiographic deterioration in rheumatoid arthritis? N. Engl. J. Med. 309:1983;1023-1028.
6. Scot D. L., Symmons D. P. M., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: Results after 20 years. Lancet. 1:1987;1108-1111.
7. Lorenzo J. A. The role of cytokines in the regulation of local bone resorption. Crit. Rev. Immunol. 11:1991;195-213.
8. Dinarello C. A. Biology of interleukin-1. FASEB J. 2:1988;108-115.
9. Lorenzo J. A., Sousa S. L., Alander C., Rasisz L. G., Dinarello C. A. Comparison of the bone-resorbing activity in the supernatants from phytohemagglutinin-stimulated human peripheral blood mononuclear cells with that of cytokines through the use of an antiserum to interleukin-1. Endocrinology. 121:1987;1164-1170.
10. Boyce B. F., Aufdemorte T. B., Garrett R., Yates A. J. P., Mundy G. R. Effects of interleukin-1 on bone turnover in normal mice. Endocrinology. 125:1989;1142-1150.
11. Klein D. C., Raisz L. G. Prostaglandins: Stimulation of bone resorption in tissue culture. Endocrinology. 86:1970;1436-1440.
12. Campbell I. K., Piccoli D. S., Butler D. M., Singleton D. K., Hamilton J. A. Recombinant human interleukin-1 stimulates human articular cartilage to undergo resorption and human chondrocytes to produce both tissue- and urokinase-type plasminogen activator. Biochim. Biophys. Acta. 967:1988;183-194.
13. Arend W. P., Dayer J-M. Inhibition of the production and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum. 38:1995;151-160.
14. Eastgate J. A., Wood N. C., Di Giovine F. S., Symons J. A., Grinlinton F. M., Duff G. W. Correlation of plasma interleukin-1 levels with disease activity in rheumatoid arthritis. Lancet. 2:1988;706-709.
15. Kahle P., Saal J. G., Schaudt K., Zacher J., Fritz P., Pawelec G. Determination of cytokines in synovial fluids: Correlation with diagnosis and histomorphological characteristics of synovial tissue. Ann. Rheum. Dis. 51:1992;731-734.
16. Campbell I. K., Piccoli D. S., Roberts M. J., Muirden K. D., Hamilton J. A. Effects of tumor necrosis factor α and b on resorption of human articular cartilage and production of plasminogen activator by human articular chondrocytes. Arthritis Rheum. 33:1990;542-552.
17. Pettipher E. R., Higgs G. A., Henderson B. Interleukin-1 induces leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA. 82:1985;1204-1208.
18. Benton H. P., Tyler J. A. Inhibition of cartilage proteoglycan synthesis by interleukin-1. Biochem. Biophys. Res. Commun. 154:1988;421-428.
19. Tyler J. A. Chondrocyte mediated depletion of articular cartilage in vitro. Biochem. J. 225:1985;493-507.
20. Benton H. P. Similar regulation of chondrocyte functions by cellular stimulants of unknown mechanism: Retinoids, cytokines, and bacterial lipopolysaccharide. Biochem. Pharmacol. 39:1990;1-6.
21. Tyler J. A. Articular cartilage cultured with catabolin (pig interleukin-1) synthesises a decreased number of normal proteoglycan molecules. Biochem. J. 227:1985;869-878.
22. Tyler J. A., Benton H. P. Synthesis of type II collagen is decreased in cartilage cultured with interleukin-1 while the rate of intracellular degradation remains unchanged. Coll. Relat. Res. 8:1988;393-405.
23. Hamilton J. A. Hypothesis: In vitro evidence for the invasive and tumor-like properties of the rheumatoid pannus. J. Rheumatol. 10:1983;845-851.
24. Lack C. H., Rogers J. H. Action of plasmin on cartilage. Nature. 182:1958;948-949.
25. Mochan E., Uhl J. Elevations in synovial fluid plasminogen activator in patients with rheumatoid arthritis. J. Rheumatol. 11:1984;123-128.
26. Postlethwaite A. E., Raghow R., Stricklin G. P., Poppleton H., Seyer J. M., Kang A. H. Modulation of fibroblast functions by interleukin-1: Increased steady-state accumulation of type I procollagen messenger RNAs and stimulation of other functions but not chemotaxis by human recombinant interleukin-1 α and b. J. Cell Biol. 106:1988;311-318.
27. Raines E. W., Dower S. K., Ross R. interleukin-1 mitogenic activity for fibroblasts and smooth muscle cells is due to PDGF-AA. Science. 243:1989;393-396.
28. Colotta F., Re F., Polentarutti N., Sozzani S., Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 80:1992;2012-2020.
29. Barrett A. J. The possible role of neutrophil proteinases in damage to articular cartilage. Agents Actions. 43:1994;194-201.
30. Pettipher E. R., Higgs G. A., Henderson B. Interleukin-1 leukocyte infiltration and cartilage proteoglycan degradation in the synovial joint. Proc. Natl. Acad. Sci. USA. 83:1986;8749-8753.
31. Chandrasekhar S., Harvey A. K., Hrubey P. S., Bendele A. M. Arthritis induced by interleukin-1 is dependent on the site and frequency of intra-articular injection. Clin. Immunol. Immunopathol. 55:1990;382-400.
32. Arend W. P. Interleukin-1 receptor antagonist: A new member of the interleukin-1 family. J. Clin. Invest. 88:1991;1445-1451.
33. Dinarello C. A., Thompson R. C. Blocking IL-1: Interleukin-1 receptor antagonist in vivo and in vitro. Immunol. Today. 12:1991;404-410.
34. Firestein G. S., Boyle D. L., Yu C. Synovial interleukin-1 receptor antagonist and interleukin-1 balance in rheumatoid arthritis. Arthritis Rheum. 37:1994;644-652.
35. Eisenberg S. P., Evans R. J., Arend W. P. Primary structure and functional expression from complementary DNA of a human interleukin-1 receptor antagonist. Nature. 343:1990;341-346.
36. McIntyre K. W., Stepan G. J., Kokinsky K. D. Inhibition of interleukin-1 (IL-1) binding and bioactivity in vitro and modulation of acute inflammation in vivo by IL-1 receptor antagonist and anti-IL-1 receptor monoclonal antibody. J. Exp. Med. 173:1991;931-939.
37. Lebsack M. E., Paul C. C., Bloedow D. C. Subcutaneous IL-1 receptor antagonist in patients with rheumatoid arthritis (abstract). Arthritis Rheum. 34:1991;S45.
38. Weinblatt M. E., Coblyn J. S., Fox D. A. Efficacy of low-dose oral pulse methotrexate in rheumatoid arthritis. N. Engl. J. Med. 312:1985;818-822.
39. Tariq S., Tariq S. M. Methotrexate in rheumatoid arthritis: Can current knowledge and experience justify its use as a first-line disease-modifying agent? Postgrad. Med. J. 69:1993;775-780.
40. Chang D. M., Baptiste P., Schur P. H. The effect of anti rheumatic drugs on interleukin-1 activity and IL-1 and IL-1 inhibitor production by human monocytes. J. Rheumatol. 17:1990;1148-1157.
41. Chang D. M., Weinblatt M. E., Schur P. H. The effects of methotrexate on interleukin-1 in patients with rheumatoid arthritis. J. Rheumatol. 19:1992;1678-1682.
42. Danis V. A., Franic G. M., Rathjen D. A., Laurent R. M., Brooks P. M. Circulating cytokine levels in patients with rheumatoid arthritis: Results of a double blind trial with sulphasalazine. Ann. Rheum. Dis. 51:1992;946-950.
43. Beutler B., Krochin N., Milsark I. W., Luedke C., Cerami A. Control of cachectin (tumor necrosis factor) synthesis: Mechanisms of endotoxin resistance. Science. 232:1986;977-980.
44. Lee S. W., Tsou A-P., Chan H. Glucocorticoids selectively inhibit the transcription of the interleukin-1 beta gene and decrease the stability of interleukin-1 beta mRNA. Proc. Natl. Acad. Sci. USA. 85:1988;1204-1208.
45. Smith M. A., Knight S. M., Maddison P. J., Smith J. G. Anemia of chronic disease in rheumatoid arthritis: Effect of the blunted response to erythropoietin and of interleukin-1 production by marrow macrophages. Ann. Rheum. Dis. 51:1992;753-757.
46. Cerami A., Tracey K. J., Lowry S. F., Beutler B. Cachectin: A pluripotent hormone released during the host response to invasion. Recent Prog. Horm. Res. 43:1987;99-112.
47. Beutler B., Cerami A. Cachectin: More than a tumor necrosis factor. N. Engl. J. Med. 316:1987;479-485.
48. Tracey K. J., Vlassara H., Cerami A. Cachectin/tumor necrosis factor. Lancet. ii:1989;1122-1126.
49. Stashenko P., Dewhirst F. E., Peros W. J., Kent R. L., Ago J. M. Synergistic interactions between interleukin-1, tumor necrosis factor, and lymphotoxin in bone resorption. J. Immunol. 138:1987;1464-1468.
50. Bertolini D. R., Nedwin G. E., Bringman T. S., Smith D. D., Mundy G. R. Stimulation of bone resorption and inhibition of bone formation in vitro by human tumor necrosis factors. Nature. 319:1986;516-518.
51. Canalis E. Effects of tumor necrosis factor on bone formation in vitro. Endocrinology. 121:1987;1596-1604.
52. Centrella M., McCarthy T. L., Canalis E. Tumor necrosis factor-alpha inhibits collagen synthesis and alkaline phosphatase activity independently of its effect on deoxyribonucleic acid synthesis in osteoblast-enriched bone cell cultures. Endocrinology. 123:1988;1442-1448.
53. Tshjian A. H. Jr., Voelkel E. F., Lazzaro M., Goad D., Bosma T., Levine L. Tumor necrosis factor-alpha (cachectin) stimulates bone resorption in mouse calvaria via a prostaglandin-mediated mechanism. Endocrinology. 120:1987;2029-2036.
54. Johnson R. A., Boyce B. F., Mundy G. R., Roodman G. D. Tumors producing human tumor necrosis factor induce hypercalcemia and osetoclastic bone resorption in nude mice. Endocrinology. 124:1989;1424-1427.
55. Sakalatvala J. Tumour necrosis factor α stimulates resorption and inhibits synthesis of proteoglycan in cartilage. Nature. 322:1986;547-549.
56. Dayer J-M., Beutler B., Cerami A. Cachectin/tumor necrosis factor stimulates collagenase and prostaglandin E2 production by human synovial cells and dermal fibroblasts. J. Exp. Med. 162:1985;2163-2168.
57. Steinberg J. J., Hubbrad J. R., Sledge C. B. Chondrocyte-mediated breakdown of cartilage. J. Rheumatol. 14:1987;55-58.
58. Takahashi N., Matsubara T., Shibanuma N., Saegusa Y., Hirohata K. Basic fibroblast growth factor (bFGF) in synovial fluid and synovial cells of rheumatoid arthritis. Arthritis Rheum. 34:1991;S118.
59. Peacock D. J., Banquerigo M. L. C., Brahn E. Angiogenesis inhibition suppresses collagen arthritis. J. Exp. Med. 175:1992;1135-1138.
60. Brennan F. M., Field M., Chu C. Q., Feldman M., Maini R. N. Cytokine expression in rheumatoid arthritis. Br. J. Rheumatol. 30:1991;76-80.
61. Chantry D., Weinarls C. G., Maini R. N., Feldman M. Mechanism of immune complex mediated damage: Induction of interleukin-1 by immune complexes and synergy with interferon-gamma and tumour necrosis factor α Eur. J. Immunol. 19:1989;189-192.
62. Pratta M. A., Di Meo T. M., Ruhl D. M., Arner E. C. Effect of interleukin-1β and tumor necrosis factor-α on cartilage proteoglycan metabolism in vitro. Agents Actions. 27:1989;250-253.
63. Bachwich P. R., Chensue S. W., Larrick J. W., Kunkel S. L. Tumor necrosis factor stimulates interleukin-1 and prostaglandin E2 production in resting macrophages. Biochem. Biophys. Res. Commun. 136:1986;94-101.
64. Nawroth P. P., Bank I., Handley D., Cassimeris J., Chess L., Stern D. Tumor necrosis factor/cachectin interacts with endothelial cell receptors to induce release of interleukin-1. J. Exp. Med. 163:1986;1363-1375.
65. Tiku K., Thakker-Varia S., Ramachandrula A., Tiku M. K. Articular chondrocytes secrete IL-1, express membrane IL-1, and have IL-1 inhibitory activity. Cell. Immunol. 140:1992;1-20.
66. Wilbrink B., Nietfeld J. J., den Otter W., van Roy J. L. A. M., Bijlasma J. W. J., Huber-Bruning O. Role of TNF-α in relation to IL-1 and IL-6 in the proteoglycan turnover of human articular cartilage. Br. J. Rheumatol. 30:1991;265-271.
67. Leong W. S., Russell R. G. G., Caswell A. M. Induction of enhanced responsiveness of human articular chondrocytes to extracellular ATP by tumour necrosis factor-α Clin. Sci. 85:1993;569-575.
68. Tetta C., Camussi G., Modena V., Vittorio C. D., Baglioni C. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann. Rheum. Dis. 49:1990;665-667.
69. Saxne T., Palladino M. A. Jr., Heinegard D., Talal N., Wollkeim F. A. Detection of tumour necrosis factor α but not tumour necrosis factor b in rheumatoid arthritis synovial fluid and serum. Arthritis Rheum. 31:1988;1041-1045.
70. Yocum D. E., Esparza L., Dubry S., Benjamin J. B., Volz R., Scuderi P. Characteristics of tumour necrosis factor production in rheumatoid arthritis. Cell. Immunol. 122:1989;131-135.
71. Manicourt D-H., Triki R., Fukuda K., Devogelaer J-P., De Deuxchaisnes C. N., Thonar E. J. M. A. Levels of circulating tumour necrosis factor α and interleukin-6 in patients with rheumatoid arthritis. Relationship to serum levels of hyaluronan and antigenic keratan sulphate. Arthritis Rheum. 36:1993;490-499.
72. Husby G., Williams R. C. Jr. Synovial localisation of tumour necrosis factor in patients with rheumatoid arthritis. J. Autoimmun. 1:1988;363-371.
73. Feldmann M., Brennan F. M., Chantry D. Cytokine production in the rheumatoid joint: Implications of treatment. Ann. Rheum. Dis. 49:1990;480-486.
74. Brahn E., Peacock D. J., Banqueirgo M. L., Liu D. Y. Effects of tumor necrosis factor alpha (TNF-α) on collagen arthritis. Lymphokine Cytokine Res. 11:1992;253-256.
75. Williams R. O., Feldman M., Maini R. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA. 89:1992;9784-9788.
76. Keffer J., Probert L., Cazalaris H. Transgenic mice expressing human tumour necrosis factor: A predictive genetic model of arthritis. EMBO J. 10:1991;4025-4031.
77. Gray P. W., Barett K., Chantry D., Turner M., Feldman M. Cloning of human tumor necrosis factor (TNF) receptor cDNA and expressing of recombinant soluble TNF-binding protein. Proc. Natl. Acad. Sci. USA. 87:1990;7380-7384.
78. Brennan F. M., Gibbons D. L., Mitchell T., Cope A. P., Maini R. N., Feldmann M. Enhanced expression of TNF receptor mRNA and protein in mononuclear cells isolated from rheumatoid arthritis synovial joints. Eur. J. Immunol. 22:1992;1907-1912.
79. Deleuran B. D., Chu C-Q., Field M. Localization of tumor necrosis factor receptors in the synovial tissue and cartilage-pannus junction in patients with rheumatoid arthritis: Implications for local actions of tumor necrosis factor α Arthritis Rheum. 35:1992;1160-1169.
80. Cope A. P., Aderka D., Doherty M. Increased levels of soluble tumor necrosis factor receptor in the sera and synovial fluid of patients with rheumatic disease. Arthritis Rheum. 35:1992;1160-1169.
81. Barrera P., Boerbooms A. M. T., Janssen E. M. Circulating soluble tumor necrosis factor receptors, interleukin-2 receptors, tumor necrosis factor α, and interleukin-6 levels in rheumatoid arthritis: Longitudinal evaluation during methotrexate and azathioprine therapy. Arthritis Rheum. 36:1993;1070-1079.
82. Firestein G. S., Paine M. M., Boyle D. L. Mechanisms of methotrexate action in rheumatoid arthritis. Arthritis Rheum. 37:1994;193-200.
83. Hale L. P., Martin M. E., McCollum D. E. Immunohistologic analysis of the distribution of cell adhesion molecules within the inflammatory synovial microenvironment. Arthritis Rheum. 32:1989;22-30.
84. Tessier P., Audette M., Cattaruzzi P., McColl S. R. Up-regulation by tumor necrosis factor α of intracellular adhesion molecule 1 expression and function in synovial fibroblasts and its inhibition by glucocorticoids. Arthritis Rheum. 36:1993;1528-1539.
85. Chin J. E., Winterrowd G. E., Krzesicki R. F., Sanders M. E. Role of cytokines in inflammatory synovitis: The coordinate regulation of intracellular adhesion molecule 1 and HLA class I and class II antigens in rheumatoid synovial fibroblasts. Arthritis Rheum. 33:1990;1776-1786.
86. Krzesicki R. F., Fleming W. F., Winterrowd G. E., Hatfield C. A., Sanders M. E., Chin J. E. T-lymphocyte adhesion to human synovial fibroblasts: Role of cytokines and the interaction between intercellular adhesion molecule 1 and CD11a/CD18. Arthritis Rheum. 34:1991;1245-1253.
87. Iigo Y., Takashi T., Tamatani T. ICAM-1-dependent pathway is critically involved in the pathogenesis of adjuvant arthritis in rats. J. Immunol. 147:1991;4167-4170.
88. Roodman G. D. Mechanisms of erythroid suppression in the anemia of chronic disease. Blood Cells. 13:1987;171-184.
89. Roubenoff R., Roubenoff R. A., Ward L. M., Holland S. M., Hellmann D. B. Rheumatoid cachexia: Depletion of lean body mass in rheumatoid arthritis. Possible association with tumor necrosis factor. J. Rheumatol. 19:1992;1505-1510.
90. Elliott M. J., Maini R. N., Feldmann M. Treatment of rheumatoid arthritis with chimeric monoclonal antibodies to tumor necrosis factor α Arthritis Rheum. 36:1993;1681-1690.
91. Elliott M. J., Maini R. N., Feldmann M. Randomised double-blinded comparison of chimeric monoclonal antibodies to tumor necrosis factor α (cA2) versus placebo in rheumatoid arthritis. Lancet. 344:1994;1105-1110.
92. Elliott M. J., Maini R. N., Feldmann M. Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis. Lancet. 344:1994;1125-1127.
93. Hirano T., Akira S., Taga T., Kishimoto T. Biological and clinical aspects of interleukin-6. Immunol. Today. 11:1990;443-449.
94. Wong G. G., Clark S. C. Multiple actions of interleukin-6 within a cytokine network. Immunol. Today. 9:1988;137-139.
95. Kurihara N., Bertolini D., Suda T., Akiyama Y., Roodman G. D. IL-6 stimulates osteoclast-like multinucleated cell formation in long term human marrow cultures by inducing IL-1 release. J. Immunol. 144:1990;4226-4230.
96. Bender S., Haubeck H. D., Van de Leur E. Interleukin-1 beta induces synthesis and secretion of interleukin-6 in human chondrocytes. FEBS Lett. 263:1990;321-324.
97. Arend W. P., Dayer J-M. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 33:1990;305-315.
98. Houssiau F. A., Devogelaer J-P., vanDamme J., Nagant de Deuxchaisnes C., vanSnick J. Interleukin-6 in synovial fluid and serum of patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 31:1988;784-788.
99. Arvidson N. G., Gudbjornsson B., Elfman L., Ryden A-C., Totterman T. H., Hallgren R. Circadian rhythm of serum interleukin-6 in rheumatoid arthritis. Ann. Rheum. Dis. 53:1994;521-524.
100. VanLeeuwen M. A., Westra J., Limburg P. C., Van Riel P. L. C. M., Van Rijswijk M. H. Interleukin-6 in relation to other pro inflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann. Rheum. Dis. 54:1995;33-38.
101. Guerne P-A., Zuraw B. L., Vaughan J. H., Carson D. A., Lotz M. Synovium as a source of interleukin-6 in vitro: Contribution to local and systemic manifestations of arthritis. J. Clin. Invest. 83:1989;585-592.
102. Hirano T., Matsuda T., Turner M. Excessive production of interleukin-6/B cell stimulatory factor-2 in rheumatoid arthritis. Eur. J. Immunol. 18:1988;1797-1801.
103. Hirano T., Taga T., Yasukawa K. Human B-cell differentiation factor defined by an anti-peptide antibody and its possible role in autoantibody production. Proc. Natl. Acad. Sci. USA. 84:1987;228-231.
104. Wahl S. M., McCartney-Francis N., Mergenhagen S. E. Inflammatory and immunomodulatory roles of TGF-β Immunol. Today. 10:1989;258-261.
105. Barnard J. A., Lyons R. M., Moses H. L. The cell biology of transforming growth factor b. Biochim. Biophys. Acta. 1032:1990;79-87.
106. Border W. A., Noble N. A. Transforming growth factor b in tissue fibrosis. N. Engl. J. Med. 331:1994;1286-1292.
107. Wahl S. M., Allen J. B., Dougherty S. F., Ellingswoth L. R. Antagonistic and agonistic effects of transforming growth factor-β and IL-1 in rheumatoid synovium. J. Immunol. 145:1990;2514-2519.
108. Tashjian A. H., Voekel E. F., Lasaro M. Alpha and beta human transforming growth factors stimulate prostaglandin production and bone resorption in cultured mouse clavaria. Proc. Natl. Acad. Sci. USA. 82:1985;4535-4538.
109. Hattersley G., Chambers T. J. Effects of transforming growth factor beta 1 on the regulation of osteoclastic development and function. J. Bone Miner. Res. 6:1991;165-172.
110. Marusic A., Kalinowski J. F., Harrison J. R., Centrella M., Raisz L. G., Lorenzo J. A. Effects of transforming growth factor-β and IL-1α on prostaglandin synthesis in serum-deprived osteoblastic cells. J. Immunol. 146:1991;2633-2638.
111. Miossec P., Naviliat M., D'Angeac A. D., Sany J., Banchereau J. Low levels of interleukin-4 and high levels of transforming growth factor b in rheumatoid synovitis. Arthritis Rheum. 33:1990;1180-1187.
112. Lotz M., Kekow J., Carson D. A. Transforming growth factor-β and cellular immune responses in synovial fluids. J. Immunol. 144:1990;4189-4194.
113. Allen J. B., Manthey C. L., Hand A. R., Ohura K., Ellingsworth L., Wahl S. M. Rapid onset of synovial inflammation and hyperplasia induced by transforming growth factor b. J. Exp. Med. 171:1990;231-247.
114. Fava R. A., Oslen N. J., Postlethwaite A. E. Transforming growth factor b1 (TGF/b1) induced neutrophil recruitment to synovial tissues: Implications for TGF-β1 driven inflammation and synovial hyperplasia. J. Exp. Med. 173:1991;1121-1132.
115. Cooper W. O., Fava R. A., Gates C. A., Cremer M. A., Townes A. S. Acceleration of onset of collagen-induced arthritis by intra-articular injection of tumor necrosis factor or transforming growth factor-beta. Clin. Exp. Immunol. 89:1991;244-250.
116. Groopamn J. E., Molina J-M., Scadden D. T. Hematopoietic growth factors. N. Engl. J. Med. 321:1989;1449-1459.
117. Xu W-D., Firestein G. S., Taetle R., Kaushansky K., Zvaifler N. J. Cytokines in chronic inflammatory arthritis. II. Granulocyte-macrophage colony-stimulating factor in rheumatoid synovial effusions. J. Clin. Invest. 83:1989;876-882.
118. Williamson D. J., Begley C. G., Vadas M. A., Metcalf D. The detection and initial characterization of colony stimulating factors in synovial fluid. Clin. Exp. Immunol. 72:1988;67-73.
119. Fischer H-G., Frosch S., Reske K., Reske-Kunz A. B. Granulocyte macrophage colony-stimulating factor activates macrophages derived from bone marrow cultures to synthesis of MHC class II molecules and to augmented antigen presentation function. J. Immunol. 141:1988;3883-3888.
120. Heidenreich S., Gong J-H., Schmidt A., Nain M., Gemsa D. Macrophage activation by granulocyte/macrophage colony stimulating factor. Priming for enhanced release of tumor necrosis factor-alpha and prostaglandin E2. J. Immunol. 143:1989;1198-1205.
121. Alvaro-Gracia J. M., Zvaifler N. J., Firestein G. S. Cytokines in chronic inflammatory arthritis IV. Granulocyte/macrophage colony-stimulating factor-mediated induction of class II MHC antigen on human monocytes: A possible role in rheumatoid arthritis. J. Exp. Med. 170:1989;865-875.
122. Burmester G. R., Jahn B., Rohwer P., Zacher J., Winchester R. J., Kalden J. R. Differential expression of Ia antigens by rheumatoid synovial lining cells. J. Clin. Invest. 80:1987;595-604.
123. Wang J. M., Colella M. S., Allavena P., Mantagani A. Chemotactic activity of human recombinant granulocyte-macrophage colony stimulating factor. Immunology. 60:1987;439-444.
124. Weisbart R. H., Kacena A., Schuh A., Golde D. W. GM-CSF induces human neutrophil IgA-mediated phagocytosis by an IgA Fc receptor activation mechanism. Nature. 332:1988;647-648.
125. Lopex A. F., Nicola N. A., Burgess A. W. Activation of granulocyte cytotoxic function by purified mouse colony-stimulating factors. J. Immunol. 131:1983;2983-2988.
126. Weisbart R. H., Golde D. W., Clark S. C., Wong G. G., Gasson J. C. Human granulocyte-macrophage colony-stimulating factor is a neutrophil activator. Nature. 314:1985;361-365.
127. Haworth C., Brennan F. M., Chantry D., Turner M., Maini R. N., Feldman M. Expression of granulocyte-macrophage colony stimulating factor in rheumatoid arthritis: Regulation by tumor necrosis factor-α Eur. J. Immunol. 21:1991;2575-2579.
128. Alvaro-Gracia J. M., Zvaifler N. J., Brown C. B., Kaushansky K., Firestein G. S. Cytokines in chronic inflammatory arthritis. IV. Analysis of the synovial cells involved in granulocyte macrophage colony-stimulating factor production and gene expression in rheumatoid arthritis and its regulation by IL-1 and tumor necrosis factor-α J. Immunol. 146:1991;3365-3371.
129. Metcalf D. The leukemia inhibitory factor (LIF). Int. J. Cell Cloning. 9:1991;95-108.
130. Lotz M., Moats T., Villiger P. M. Leukemia inhibitory factor is expressed in cartilage and synovium and can contribute to the pathogenesis of arthritis. J. Clin. Invest. 90:1992;888-896.
131. Villiger P. M., Geng Y., Lotz M. Induction of cytokine expression by leukemia inhibitory factor. J. Clin. Invest. 91:1993;1575-1581.
132. Waring P. M., Carroll G. L., Kandiah D. A., Buirski G., Metcalf D. Increased levels of leukemia inhibitory factor in synovial fluid from patients with rheumatoid arthritis and other inflammatory arthritides. Arthritis Rheum. 36:1993;911-915.
133. Campbell I. K., Waring P., Novak U., Hamilton J. A. Production of leukemia inhibitory factor by human articular chondrocytes and cartilage in response to interleukin-1 and tumor necrosis factor α Arthritis Rheum. 36:1993;790-794.
134. Reid I. R., Lowe C., Carnish J. Leukemia inhibitory factor: A novel bone-active cytokine. Endocrinology. 126:1990;1416-1420.
135. Cornish J., Callon K., King A., Edgar S., Reid I. R. The effect of leukemia inhibitory factor on bone in vivo. Endocrinology. 132:1993;1359-1366.
136. Noda M., Vogel R. L., Hasson D. M., Rodan G. A. Leukemia inhibitory factor suppresses proliferation, alkaline phosphatase activity, and type I collagen messenger ribonucleic acid level and enhances osteopontin mRNA level in murine osteoblast-like (MC3T3E1) cells. Endocrinology. 127:1990;185-190.
137. Hamilton J. A., Waring P. M., Filonzi E. L. Induction of leukemia inhibitory factor in human synovial fibroblasts by IL-1 and tumor necrosis factor-α J. Immunol. 150:1993;1496-1502.
138. Ishimi Y., Abe E., Jin C. H. Leukemia inhibitory factor/differentiation-stimulation factor (LIF/D-Factor): Regulation of its production and possible roles in bone metabolism. J. Cell. Physiol. 152:1992;71-78.
139. Greenwald R. A. Oxygen radicals, inflammation, and arthritis: Pathophysiological consideration and implications for treatment. Semin. Arthritis Rheum. 20:1911;219-240.
140. Halliwell B., Gutteridge J. M. C., Cross C. E. Free radicals, antioxidants, and human disease: Where are we now? J. Lab. Clin. Med. 119:1992;598-620.
141. Shingu M., Isayama T., Yasutake C. Role of oxygen radicals and IL-6 in IL-1-dependent cartilage matrix degradation. Inflammation. 18:1994;613-623.
142. Newcombe H. L., Bucknall R. C., Eduwards S. W. Neutrophils isolated from the synovial fluid of patients with rheumatoid arthritis: Priming and activation in vivo. Ann. Rheum. Dis. 50:1991;147-153.
143. Maly F. E., Cross A. R., Jones O. T. G. The superoxide generation system of B cell lines. J. Immunol. 140:1988;2334-2339.
144. Zweier J. L., Kuppusamy P., Lutty G. A. Measurement of endothelial cell free radical generation. Evidence for a central mechanism of free radical injury in postischemic tissue. Proc. Natl. Acad. Sci. USA. 85:1988;4046-4050.
145. Blake D. R., Merry P., Unsworth J. Hypoxic-reperfusion injury in the inflamed human joint. Lancet. i:1989;289-293.
146. Klebanoff S. J., Vada M. A., Harlan J. M. Stimulation of neutrophils by tumor necrosis factor. J. Immunol. 136:1986;4220-4225.
147. Tsujimoto M., Yokota S., Vilcek J., Weissmann G. Tumor necrosis factor provokes superoxide anion generation from neutrophils. Biochem. Biophys. Res. Commun. 137:1986;1094-1101.
148. M. L. Tiku, J. B. Leisch, F. M. Robertson, 1988, Chondrocytes produce oxygen radicals after treatment with ConA, gamma interferon or tumor necrosis factor, Proceedings of the 52nd Annual Meeting of the American Rheumatism Association, American Rheumatism Association, Houston, TX.
149. Dean R. T., Robert C. R., Forni L. G. Oxygen-centered free radicals can efficiently degrade the polypeptide of proteoglycans in whole cartilage. Biosci. Rep. 4:1984;1017-1026.
150. Halliwell B., Gutteridge J. M. C. The importance of free radicals and catalytic metal ions in human diseases. Mol. Aspects Med. 8:1985;89-193.
151. Bates E. J., Johnson C. C., Lother D. A. Inhibition of proteoglycan synthesis by hydrogen peroxide in cultured bovine articular cartilage. Biochim. Biophys. Acta. 838:1985;221-228.
152. Greenwald R. A., Moy W. W., Lazarus D. Degradation of cartilage proteoglycans and collagen by superoxide radical. Arthritis Rheum. 19:1976.
153. Dabbagh A., Morris C. J., Blake D. R. Hydrogen peroxide-initiated animal model of acute inflammation. Br. J. Rheumatol. 28:1989;45-51.
154. Lunec J., Blake D. R. Determination of dehydroascorbic acid and ascorbic acid in serum and synovial fluid of patients with rheumatoid arthritis. Free Radical Res. Commun. 1:1986;31-41.
155. Wong P. S., Travis J. Isolation and properties of oxidised alpha-1-proteinase inhibitor from human rheumatoid synovial fluid. Biochem. Biophys. Res. Commun. 96:1980;1449-1454.
156. Rowley D. A., Gutteridge J. M. C., Blake D. R., Farr M., Halliwell B. Lipid peroxidation in rheumatoid arthritis: Thiobarbituric acid-reactive material and catalytic iron salts in synovial fluid from rheumatoid patients. Clin. Sci. 66:1984;691-695.
157. Heliovaara M., Knekt P., Aho K., Aaran R-K., Alfthan G., Aromaa A. Serum antioxidants and risk of rheumatoid arthritis. Ann. Rheum. Dis. 53:1994;51-53.
158. Honkanen V., Konttinen Y. T., Mussalo-Rauhamaa H. Vitamins A and E, retinol binding protein and zinc in rheumatoid arthritis. Clin. Exp. Rheumatol. 7:1989;465-469.
159. Imadaya A., Terasawa K., Tosa H., Okamoto M., Toriizuka K. Erythrocyte antioxidant enzymes are reduced in patients with rheumatoid arthritis. J. Rheumatol. 15:1988;1628-1631.
160. Michelson A. M., Puget K., Jadot G. Anti-inflammatory activity of superoxide dismutases: Comparison of enzymes from different sources in different models in rats: Mechanism of action. Free Radical Res. Commun. 2:1986;43-56.
161. Halliwell B., Evans P. J., Kaur H., Chirico S. Drug derived radicals: Mediators of the side effects of anti inflammatory drugs? Ann. Rheum. Dis. 51:1992;1261-1263.
162. Ueki Y., Miyake S., Tominaga Y., Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J. Rheumatol. 23:1996;230-236.
163. Stefanovic-Racic M., Stadler J., Evans C. H. Nitric oxide and arthritis. Arthritis Rheum. 36:1993;1036-1044.
164. Farrell A. J., Blake D. R., Palmer R. M. J., Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatoid diseases. Ann. Rheum. Dis. 51:1992;1219-1222.
165. Jacob T., Morrell M., Manzi S., Verdile V., Simmons R. L. Elevated nitrates in inflammatory joint disease: Nitric oxide in arthritis. Arthritis Rheum. 35:1992;R9.
166. DiRosa M., Randomski M., Carnuccio R., Moncada S. Glucocorticoids inhibit the induction of nitric oxide synthase in macrophages. Biochem. Biophys. Res. Commun. 172:1990;1246-1252.
167. Carrallo G., Chessa M. A., Pensa V., Tubaro M., Milaxxotto F., Tubaro E. Possible scavenger effect of salicylic acid on nitric oxide production in vitro. The Biology of Nitric Oxide. 1992;Portland Press, Colchester. p. 68-72.
168. Walakovits L. A., Moore V. L., Bhardwaj N., Gallick G. S., Lark M. W. Detection of stromelysin and collagenase in synovial fluid from patients with rheumatoid arthritis and posttraumatic knee injury. Arthritis Rheum. 35:1992;35-42.
169. Oleksyszyn J., Augustine A. J. Dithiocarbamates inhibit IL-1-induced cartilage degradation in bovine articular cartilage explants. Inflam. Res. 45:1996;215-217.
170. Clark I. M., Powell L. K., Ramsey S., Hazleman B. L., Cawston T. E. The measurement of collagenase, tissue inhibitor of metalloproteinases (TIMP), and collagenase-TIMP complex in synovial fluids from patients with osteoarthritis and rheumatoid arthritis. Arthritis Rheum. 36:1993;372-379.
171. Manicourt D-H., Fujimoto N., Obata K., Thonar E. J-M. A. Levels of circulating collagenase, stromelysin-1, and tissue inhibitor of matrix metalloproteinases 1 in patients with rheumatoid arthritis. Relationship to serum levels of antigenic keratan sulfate and systemic parameters of inflammation. Arthritis Rheum. 38:1995;1031-1039.
172. Vincenti M. P., Clark I. M., Brinckerhoff C. E. Using inhibitors of metalloproteinases to treat arthritis. Easier said than done? Arthritis Rheum. 37:1994;1115-1126.
173. Shingu M., Nagai Y., Isayama T., Naono T., Nobunaga M., Nagai Y. The effects of cytokines on metalloproteinase inhibitors (TIMP) and collagenase production by human chondrocytes and TIMP production by synovial cells and endothelial cells. Clin. Exp. Immunol. 94:1993;145-149.
174. Snapper C. M., Finkelman F. D., Paul W. E. Regulation of IgG1 and IgE production by interleukin-4. Immunol. Rev. 102:1988;51-75.
175. Yokota T., Arai N., de Vries J. Molecular biology of interleukin-4 and interleukin-5 genes and biology of their products that stimulate B cells, T cells and hematopoietic cells. Immunol. Rev. 102:1988;137-187.
176. Lowenthal J. W., Castle B. E., Christiansen J. Expression of high affinity receptors for murine interleukine-4 (BSF-1) on hemopoietic and nonhemopoietic cells. J. Immunol. 140:1988;456-464.
177. TeVelde A. A., Huijbens R. J. F., Heije K., De Vries J. E., Figdor C. G. Interleukin-4 (IL-4) inhibits secretion of IL-1b, tumor necrosis factor α, and IL-6 by human monocytes. Blood. 76:1990;1392-1397.
178. Hart P. H., Vitti G. F., Burgess D. R., Whitty G. A., Piccoli D. S., Hamilton J. A. Potential anti-inflammatory effects of interleukin-4: Suppression of human monocyte tumor necrosis factor α, interleukin-1, and prostaglandin E2. Proc. Natl. Acad. Sci. USA. 86:1989;3803-3807.
179. Zhou Y., Lin G., Baarsch M. J., Scamurra R. W., Murtaugh M. P. Interleukin-4 suppresses inflammatory cytokine gene transcription in porcine macrophages. J. Leukocyte Biol. 56:1994;507-513.
180. Miossec P., Briolay J., Dechanet J., Wijdenes J., Martinez Valdez H., Banchereau J. Inhibition of the production of proinflammatory cytokines and immunoglobulins by interleukin-4 in an ex vivo model of rheumatoid synovitis. Arthritis Rheum. 35:1992;874-883.
181. Miossec R., Chomarat P., Dechanet J. Interleukin-4 inhibits bone resorption through an effect on osteoclasts and pro-inflammatory cytokines in an exvivo model of bone resorption in rheumatoid arthritis. Arthritis Rheum. 37:1994;1715-1722.
182. Yeh L-A., Augustine A. J., Lee P., Riviere L. S., Sheldon A. Interleukin-4, an inhibitor of cartilage breakdown in bovine articular cartilage explants. J. Rheumatol. 22:1995;1740-1746.
183. Van Room J. A. G., Van Roy L. A. M., Duits A., Lafeber F. P. J. G., Bijlsma J. W. J. Proinflammatory cytokine production and cartilage damage due to rheumatoid synovial T helper-I activation is inhibited by interleukin-4. Ann. Rheum. Dis. 54:1995;836-840.
184. Colotta F., Re F., Muzio M. Interleukin-1 type II receptor: A decoy target for IL-1 that is regulated by IL-4. Science. 261:1993;472-475.
185. Arend W. P., Joslin F. G., Massoni R. J. Effects of immune complexes on production by human monocytes of interleukin-1 or an interleukin-1 inhibitor. J. Immunol. 134:1985;3668-3675.
186. Seckinger P., Kowenthal J. W., Williamson K., Dayer J-M., Mac Donald H. R. A urine inhibitor of interleukin-1 activity that blocks ligand bindings. J. Immunol. 139:1987;1546-1549.
187. Vannier E., Miller L. C., Dinarello C. A. Coordinated anti inflammatory effects of interleukin-4: Interleukin-4 suppresses interleukin-1 production by up-regulating gene expression and synthesis of interleukin-1 receptor antagonist. Proc. Natl. Acad. Sci. USA. 89:1992;4076-4080.
188. Colotta F., Re F., Polentarutti N., Sozzani S., Mantovani A. Modulation of granulocyte survival and programmed cell death by cytokines and bacterial products. Blood. 80:1992;2012-2020.
189. Paul W. E. Interleukin-4: A prototypic immunoregulatory lymphokine. Blood. 77:1991;1859-1870.
190. Unkeless J. C. Function and heterogeneity of human Fc receptors for immunoglobulin G. J. Clin. Invest. 83:1989;355-361.
191. Passlick B., Fleiger D., Zeigler-Heitbrock H. W. L. Identification and characterization of a novel monocyte subpopulation in human peripheral blood. Blood. 74:1989;2527-2534.
192. Clarkson S. B., Ory P. A. CD16: Developmentally regulated IgG Fc receptors on cultured monocytes. J. Exp. Med. 167:1988;408-420.
193. Welch G. R., Wong H. L., Wahl S. M. Selective induction of Fc RIII on human monocytes by transforming growth factor-β J. Immunol. 144:1990;3444-3448.
194. Welch G., Allen J., Wong H., Wahl S. Regulation of Fc RIII expression on inflammatory synovial monocytes by transforming growth factor beta. FASEB J. 4:1990;A1755.
195. Wong H. L., Welch G. R., Brandes M. E., Wahl S. M. IL-4 antagonizes induction of Fc RIII (CD16) expression by transforming growth factor-β on human monocytes. J. Immunol. 147:1991;1843-1848.
196. Sato N., Sawada K., Tarumi T. Recombinant human interleukin-4 inhibits the production of granulocyte-macrophage colony stimulating factor by blood mononuclear cells. Br. J. Haematol. 86:1994;695-701.
197. Dechant J., Taupin J-L., Chomarat P. Interleukin-4 but not interleukin-10 inhibits the production of leukemia inhibitory factor by rheumatoid synovium and synoviocytes. Eur. J. Immunol. 24:1994;3222-3228.
198. 22. J. Immunol. 143:1989;3020-3024.
199. Abramson S. L., Gallin J. I. IL-4 inhibits superoxide production by human mononuclear phagocytes. J. Immunol. 144:1990;625-630.
200. Sands W. A., Bulut V., Severn A., Xu D., Liew F. Y. Inhibition of nitric oxide synthesis by interleukin-4 may involve inhibiting the activation of protein kinase C epsilon. Eur. J. Immunol. 24:1994;2345-2350.
201. Al-Ramadi B. K., Meissler J. J. Jr., Huang D., Eisenstein T. K. Immunosuppression induced by nitric oxide and its inhibition by interleukin-4. Eur. J. Immunol. 22:1992;2249-2254.
202. Lacraz S., Nicod L., Galve-de Rochemonteix B., Baumberger C., Dayer J-M., Welgus H. G. Suppression of metalloproteinase biosynthesis in human alveolar macrophages by interleukin-4. J. Clin. Invest. 90:1992;382-388.
203. 2. J. Biol. Chem. 267:1992;515-519.
204. Prontera C., Crescenzi G., Rotilio D. Inhibition by interleukin-4 of stromelysin expression in human skin fibroblasts: Role of PKC. Exp. Cell. Res. 224:1996;183-188.
205. Shingu M., Miyauchi S., Nagai Y., Yasutake C., Horie K. The role of IL-4 and IL-6 in IL-1-dependent cartilage matrix degradation. Br. J. Rheumatol. 34:1995;101-106.
206. H1H2. Annu. Rev. Immunol. 7:1989;145-173.
207. 2. J. Immunol. 145:1990;3796-3803.
208. Margolin K., Aronson F. R., Sznol M., Atkins M. B., Gucalp R., Fisher R. I., Sunderland M., Doroshow J. H., Ernest M. L., Mier J. W. Phase II studies of recombinant human interleukin-4 in advanced renal cancer and malignant melanoma. J. Immunother. Emphasis Tumor Immunol. 15:1994;147-153.
209. Emery B. E., White M. V., Igarashi Y., Mullol J., Berkebile C., Peden D., Lotze M. T., Kalinder M. A. The effect of IL-4 on human nasal nucosal responses. J. Allergy Clin. Immunol. 90:1992;772-781.